Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS Malignancy Consortium
Gynecologic Oncology Mar 23, 2019
Einstein MH, et al. - In HIV-infected women with locally-advanced cervical cancer (LACC) receiving antiretroviral therapy (ART), researchers assessed whether concomitant chemoradiotherapy administered at standard doses in these subjects would be feasible, safe, and tolerable. They included in the analysis patients who met standard eligibility criteria with HIV infection and untreated, histologically-confirmed, invasive carcinoma of the uterine cervix, FIGO stages IB2, IIA (if tumor >4 cm), IIB, IIIA, IIIB, or IVA. The treatment regimen was 41.4–45 Gy external beam radiation therapy followed by high dose rate brachytherapy concomitant with up to six weekly doses of cisplatin 40 mg/m2. Participants were followed for 12 months. Concomitant chemoradiotherapy could be finished by most of the HIV-infected women with the identical cisplatin dose used in HIV-uninfected women; while on treatment the former patient group demonstrated similar tolerability and high ART adherence.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries